Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Iowa Chugai Pharmaceutical |
---|---|
Information provided by: | FDA Office of Orphan Products Development |
ClinicalTrials.gov Identifier: | NCT00010452 |
OBJECTIVES:
I. Determine the efficacy of picibanil sclerotherapy in children with macrocystic lymphangioma.
Condition | Intervention | Phase |
---|---|---|
Lymphatic Malformations |
Drug: picibanil |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial |
Enrollment: | 150 |
Study Start Date: | April 2000 |
Primary Completion Date: | June 2006 (Final data collection date for primary outcome measure) |
PROTOCOL OUTLINE: This is a multicenter study. Patients are stratified according to prior treatment (no prior treatment vs prior surgical treatment) and geographic area. Patients who meet all study criteria are put in the "Immediate Treatment Group." Patients receive an intralesional injection of picibanil (OK432) with the aid of ultrasonography or transillumination for localization of cysts.
Treatment repeats every 6-8 weeks for a total of up to 4 injections. After completion of treatment, patients are followed at 6 months, 1 year, and 2 years.
Ages Eligible for Study: | 6 Months to 18 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Patient Characteristics--
Other:
United States, California | |
Children's Associated Medical Group | |
San Diego, California, United States, 92123 | |
United States, Colorado | |
Children's Hospital of Denver | |
Denver, Colorado, United States, 80218 | |
United States, District of Columbia | |
Childrens National Medical Center | |
Washington, District of Columbia, United States | |
United States, Florida | |
All Children's Hospital | |
St. Petersburg, Florida, United States, 33701 | |
United States, Iowa | |
University of Iowa Hospitals and Clinics | |
Iowa City, Iowa, United States, 52242 | |
United States, Minnesota | |
Children's Hospitals and Clinics - Minneapolis | |
Minneapolis, Minnesota, United States, 55404 | |
United States, New York | |
SUNY Upstate Medical University | |
Syracuse, New York, United States, 13210 | |
United States, Oregon | |
Oregon Health Sciences University | |
Portland, Oregon, United States | |
United States, Tennessee | |
Vanderbilt University | |
Nashville, Tennessee, United States | |
United States, Texas | |
Texas Pediatric Otolaryngology Center | |
Houston, Texas, United States, 77030 | |
United States, Virginia | |
Children's Hospital of the Kings Daughter | |
Norfolk, Virginia, United States, 23507 | |
United States, Wisconsin | |
Children's Hospital of Wisconsin | |
Milwaukee, Wisconsin, United States, 53201 | |
University of Wisconsin Hospital and Clinics | |
Madison, Wisconsin, United States, 53792-0001 |
Study Chair: | Richard J Smith | University of Iowa |
Responsible Party: | University of Iowa Health Care ( Richard JH Smith, MD ) |
Study ID Numbers: | 199/15706, UIHC-FDR001774 |
Study First Received: | February 2, 2001 |
Last Updated: | March 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00010452 History of Changes |
Health Authority: | United States: Federal Government |
cystic hygroma lymphangiomas lymphatic malformations |
Lymphatic Abnormalities Lymphatic Diseases Picibanil Congenital Abnormalities Lymphangioma, Cystic |
Lymphatic Vessel Tumors Lymphatic Abnormalities Lymphatic Diseases Neoplasms Neoplasms by Histologic Type Antineoplastic Agents |
Therapeutic Uses Picibanil Congenital Abnormalities Pharmacologic Actions Lymphangioma Lymphangioma, Cystic |